BackOvid Therapeutics Overview

Ovid Therapeutics Inventory

Latest inventory for OVID: $0.

Get informed when a big investor buys or sells

+ Follow
Inventory
$0.00

Peer trimmed avg / median

Loading

Ovid Therapeutics Inventory History

Loading

Ovid Therapeutics vs. peers: Inventory Comparison

Loading

Ovid Therapeutics Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Ovid Therapeutics (OVID) FAQ

Ovid Therapeutics's inventory stands at $0 as of June 2026. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Ovid Therapeutics reported $0 in inventory versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Ovid Therapeutics's inventory evolved across reporting periods, while the comparison chart places OVID next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Ovid Therapeutics's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.